IDEXX Laboratories (IDXX) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus sits within IDEXX's guided range and the bar is not stretched, but the single biggest swing factor is whether CAG Diagnostics recurring revenue growth can sustain its Q1 momentum against a backdrop of worsening veterinary visit data and a newly cautious read-through from Zoetis.

Heading into Q2 2026, IDEXX's consensus revenue estimate of ~$1.198B implies ~8.1% reported growth, sitting comfortably within the company's guided range of 7.3%–9.3% reported growth, suggesting the bar is neither stretched nor particularly low. Management's tone at the May 27 Stifel Jaws & Paws Conference was notably confident — CEO Mike Erickson stated "we feel good about the overall forecast for the year" and reiterated that innovation (inVue Dx, Cancer DX, FNA rollout) is "really propelling our growth," with no guidance revision since the Q1 print. Estimate revisions have been essentially flat since the Q1 earnings call, with the Q2 operating EPS consensus moving from $3.93 to $3.92 — a negligible drift that reflects neither meaningful upward nor downward pressure, consistent with management's unchanged full-year framework. The stock has underperformed the broader market since Q1 earnings (IDXX +0.9% vs. SPY +4.7% indexed), weighed down by a bearish CATalyst Council report forecasting visit declines through 2030 and Zoetis's Q2 print showing flat organic growth and a guidance cut — both of which have compressed sentiment and kept the multiple from re-rating despite solid fundamentals. The key wildcard is the FNA controlled-to-unconstrained launch transition: management guided for a "full volume ramp in the second half," and any signal that FNA adoption is accelerating faster than expected in Q2 could be the catalyst that re-rates the stock, while a softer-than-expected CAG recurring revenue print amid the deteriorating visit backdrop (VetSource Q2 data: -1.9% YoY; July data: -4% YoY) would validate the bear case.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sits within guidance on all key metrics, making this a moderate bar — not a high hurdle. CAG Diagnostics recurring revenue growth is the bigger swing factor: the guided range of 8.5%–10.5% organic is wide, and where IDEXX lands within it will determine the stock's reaction more than any other single metric.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data (Total Revenue, CAG Diagnostics Recurring Revenue, EPS — Diluted Operating, Operating Income, IDEXX VetLab Consumables, Reference Lab Revenue, CAG Diagnostics Capital Instruments). Q2 2026 guidance from Q1 2026 Earnings Call (May 5, 2026). Q2 2026 guidance midpoint for revenue based on 8.3% reported growth midpoint applied to Q2 2025 actual of $1,109.5M. Operating income guidance midpoint derived from 34.1% operating margin midpoint (33.9%–34.3% guided range) applied to consensus revenue.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top 2 KPIs: Total Revenue and CAG Diagnostics Recurring Revenue

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been remarkably stable since the Q1 2026 earnings call — essentially flat revisions across all KPIs — indicating the Street is tracking guidance closely with no meaningful divergence. The lack of upward revision despite a strong Q1 beat and guidance raise suggests the market is waiting for Q2 execution proof before re-rating, leaving room for a positive surprise if IDEXX delivers at or above the top of its guided range.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of May 12, 2026 (5 trading days post Q1 2026 earnings). Guidance from Q1 2026 Earnings Call (May 5, 2026). Estimate revisions are negligible across all KPIs, confirming the Street is anchored to guidance midpoints with no material drift in either direction since the Q1 print.

5. Stock Performance

Key Takeaway: IDXX has meaningfully underperformed both the sector ETF (IHI +8.9%) and the S&P 500 (+4.7%) since Q1 2026 earnings, with the stock essentially flat (+0.9%) — a divergence driven by sentiment compression from the CATalyst Council visit-decline report and the Zoetis Q2 guidance cut, not by estimate revisions (which have been flat). This underperformance creates an asymmetric setup: if IDEXX delivers at or above the top of its guided range, the multiple re-rating potential is meaningful given the stock is trading at a discount to its recent sentiment-driven peak.

IDXX vs. iShares US Medical Devices ETF (IHI) vs. S&P 500 — Indexed to 100 at May 5, 2026 (Q1 2026 Earnings). Sector ETF: iShares U.S. Medical Devices ETF (IHI) — selected as the closest available proxy for the medical devices/diagnostics sub-sector. Source: Stock Price Data (Yahoo Finance).

• IDXX performance since Q1 2026 earnings (May 5, 2026 close $562.97 → Aug 4, 2026 close $567.84): +0.9% (indexed to 100.9)
• IHI (iShares US Medical Devices ETF) over same period: +8.9% (indexed to 108.9) — IDXX underperformed the sector ETF by ~800 bps
• S&P 500 (SPY) over same period: +4.7% (indexed to 104.7) — IDXX underperformed the market by ~380 bps
• Key driver of underperformance: Sentiment compression from (1) CATalyst Council report (published during Q2) forecasting vet visit declines through 2030 with a FY2027 trough of -2.2%, which pressured IDXX shares; and (2) Zoetis Q2 2026 print (reported ~Aug 3, 2026) showing flat organic revenue growth and a full-year guidance cut amid softer U.S. companion-animal demand and fewer vet visits — a direct negative read-through for IDXX.
• Estimate revisions were NOT the driver: Q2 2026 EPS consensus moved from $3.93 to $3.92 since the Q1 print — essentially flat. The underperformance is entirely sentiment/multiple-driven, not fundamentals-driven.
• Notable events marked on chart: Stifel Jaws & Paws Conference (May 27, 2026) — CEO Erickson reaffirmed full-year confidence; Q2 Earnings Date Announced (July 1, 2026) — August 4, 2026 BMO confirmed.

Source: Stock Price Data (Yahoo Finance). Indexed prices computed from close-to-close series.

6. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer commentary from the last 60 days presents a mixed-to-cautious read-through for IDXX's Q2 2026 print. Zoetis's Q2 2026 result (flat organic growth, guidance cut) is the most direct and negative read-through, confirming that U.S. vet visit headwinds persisted through Q2; however, Elanco's more constructive commentary on the U.S. pet health market (March/April rebound, high-single-digit full-year growth) and IDXX's own differentiated innovation platform (inVue Dx, Cancer DX, reference lab momentum) suggest IDXX may be better insulated than the sector-wide narrative implies.

Zoetis (ZTS) — Q2 2026 Earnings / William Blair Conference (June 2, 2026)

Read-Through Relevance: HIGH — Negative. Zoetis is the most direct animal health peer and its Q2 2026 result is the single most important read-through for IDXX heading into tomorrow's print.

• Flat organic revenue growth in Q2 2026; full-year guidance cut: Zoetis reported flat organic revenue growth in Q2 2026 and lowered its full-year guidance, citing "softer U.S. companion-animal demand, fewer veterinary visits and a more competitive market." This is a direct negative read-through for IDXX's CAG Diagnostics recurring revenue, which is highly correlated with vet visit volumes. (Source: Diamond Hill Capital Q2 2026 Investor Letter / Yahoo Finance, Aug 3, 2026)
• U.S. vet visits down ~2% in Q1 2026; no improvement expected for rest of year: At the William Blair Growth Stock Conference (June 2, 2026), Zoetis management stated visits were "down about 2% in the quarter" (Q1 2026) and explicitly said they are "not expecting an uptick in terms of significant improvement in vet clinic visits for the rest of the year." This is consistent with IDXX's own -1.5% full-year visit assumption but suggests the risk is to the downside, not upside.
• Consumer behavior shift — extending dosage intervals, delaying clinic visits: Zoetis noted pet owners are "extending dosage intervals" and "delaying visits to the clinic," particularly concentrated around "large corporate clinics given the cumulative effect of price increases." This dynamic is a headwind for IDXX's reference lab and consumables businesses, which depend on visit frequency and diagnostic utilization per visit.
• Positive offset — diagnostics spending remains resilient: Zoetis noted that despite visit declines, pet owners show "strength in terms of spending on diagnostics and emergency care." This is a constructive read-through for IDXX's diagnostic utilization premium over visit trends — consistent with IDXX's own ~1,100 bps premium in Q1 2026.
• H2 2026 improvement expected from easier comps, not macro recovery: Zoetis guided for sequential improvement in H2 2026 driven by "easier comps" (9% growth H1 2025 vs. 6% full-year 2025), not a macro recovery. This is relevant for IDXX's H2 2026 FNA ramp — the improvement story is innovation-driven, not visit-driven, which is consistent with IDXX's own framing.

Elanco Animal Health (ELAN) — William Blair Growth Stock Conference (June 2, 2026)

Read-Through Relevance: MODERATE — Mixed/Constructive. Elanco's commentary is less directly comparable to IDXX (different product mix — pharma vs. diagnostics) but provides useful color on the broader U.S. pet health market trajectory for Q2 2026.

• Q1 2026 sluggish start due to weather; March/April rebound observed: Elanco noted "Q1 in 2026 was off to a sluggish start, largely driven by weather-related events in January and February that shut down clinics," but confirmed a "March and April rebound." This is a constructive read-through for IDXX's Q2 2026 — if the rebound sustained into Q2, it would support IDXX's CAG recurring revenue growth at or above the midpoint of its 8.5%–10.5% guided range.
• U.S. pet health market expected to grow low-to-mid single digits in 2026: Elanco guided for the broader U.S. pet health market to "grow low single digits to mid-single digits this year," with its own U.S. Pet Health business delivering "high single digit" full-year revenue growth. Year-to-date, "both the derm market and the parasiticide market showing positive growth." This is a more constructive backdrop than the Zoetis narrative implies.
• Corporate clinic channel growing strongly for Elanco: Elanco's corporate clinic business "grew by 12% in Q1 2026, over 2x the average of U.S. Pet Health growth rate." This is a positive read-through for IDXX's reference lab and consumables businesses, which have significant exposure to corporate clinic chains.
• No price race to the bottom; pricing discipline maintained: Elanco explicitly stated "there is no price race to the bottom" and took "the largest price increase it has ever taken in the veterinary channel in January of 2026." This is constructive for IDXX's ~4% global net price realization assumption for FY 2026.

Bank of America Animal Health Sector Note (July 28, 2026)

Read-Through Relevance: HIGH — Cautious. BofA's pre-earnings sector note provides the most current third-party data on Q2 2026 vet visit trends and sets the tone for investor expectations heading into IDXX's print.

• VetSource Q2 2026 data: vet visits -1.9% YoY — consistent with Q1 trends: VetSource data showed Q2 2026 vet visit declines of -1.9% YoY, consistent with Q1 trends and within IDXX's full-year -1.5% guidance assumption. This is broadly in-line with IDXX's planning assumptions and does not suggest a material negative surprise on the visit side.
• July 2026 data shows steeper -4% YoY decline — but likely holiday-distorted: July data showed steeper declines of -4% YoY, though BofA noted "July 4 holiday timing may have caused distortion." This is a potential H2 2026 risk for IDXX but is not directly relevant to the Q2 print.
• BofA maintains Neutral on IDXX; expects Q2 results to align with estimates: BofA maintained a Neutral rating on IDXX and expected "second-quarter results to align with estimates without major surprises." This is consistent with the flat estimate revision picture and suggests the Street is not positioned for a large beat or miss.
• CATalyst Council report — visit declines forecast through 2030 with FY2027 trough of -2.2%: During Q2, CATalyst Council (whose board includes former IDXX CEO Jon Ayers) published analysis forecasting vet visit declines continuing past 2030 with a FY2027 trough of -2.2%. BofA noted this "contributed to pressure on Idexx shares during the quarter." This is a sentiment overhang that IDXX management will need to address on the Q2 call.
• BofA expects vet visits to decline ~2% for FY 2026; no sustained improvement anticipated: BofA's full-year visit assumption of -2% is slightly worse than IDXX's own -1.5% assumption, representing a modest risk to IDXX's volume-driven growth thesis if the bank's view proves correct.

IDEXX Management — Stifel Jaws & Paws Conference (May 27, 2026)

Read-Through Relevance: HIGH — Constructive. This is IDXX management's own post-Q1 commentary on Q2 and full-year 2026 trajectory — the most direct forward-looking signal available before tomorrow's print.

• "We feel good about the overall forecast for the year": CEO Mike Erickson explicitly reaffirmed confidence in the full-year 2026 forecast at the Stifel conference, with no guidance revision. This is the clearest signal that Q2 is tracking to plan.
• Growth expected to accelerate for the balance of the year — driven by multiple factors, not just inVue Dx: Erickson stated "innovation is really propelling our growth" and characterized the business as having "many, many things contributing" — including aging pets (green shoots in dogs over 5 for three consecutive quarters), Cancer DX adoption, FNA ramp, and international expansion.
• FNA controlled-to-unconstrained launch on track for H2 2026: Management confirmed the FNA rollout is "expanding right now" and the plan is to "move from controlled to more of an unconstrained launch" in the "later part of the year." Revenue per box for inVue Dx is "comfortably in the $3,500–$5,500 band today with blood and ear" — ahead of FNA contribution, suggesting upside potential as FNA scales.
• Cancer DX gaining traction; 20% of volume from non-primary IDXX reference lab accounts: Cancer DX is "driving new customer growth" with ~20% of volume coming from practices that don't use IDXX as their primary reference lab — a meaningful competitive moat signal. Mast cell tumor indication expected to be added later in 2026, with a third undisclosed indication by year-end.
• Installed base grew 12% in Q1 2026; international placements represent 1/3 of inVue Dx: The installed base grew 12% in Q1, "really building on very solid commercial momentum." One-third of inVue Dx placements are international, supporting the international growth premium thesis.

Sources: Stifel Jaws & Paws Conference Transcript (May 27, 2026); William Blair Growth Stock Conference Transcripts — Zoetis (ZTS) and Elanco Animal Health (ELAN) (June 2, 2026); Bank of America Animal Health Sector Note (July 28, 2026, via Investing.com); Diamond Hill Capital Q2 2026 Investor Letter (Yahoo Finance, Aug 3, 2026).

7. Material News & Developments

Key Takeaway: The most important development since Q1 2026 earnings is Zoetis's Q2 2026 print (flat organic growth, guidance cut), which has directly pressured IDXX shares and set a cautious sector tone heading into tomorrow's print. The implication for IDXX is that the bar for a positive stock reaction is lower than usual — any evidence that IDXX's innovation-driven model is outperforming the sector visit headwinds could trigger a meaningful re-rating.

• ~Aug 3, 2026 — Zoetis Q2 2026: Flat organic growth, full-year guidance cut. Zoetis reported flat organic revenue growth in Q2 2026 and lowered full-year guidance, citing softer U.S. companion-animal demand, fewer vet visits, and increased competition. This is the most direct negative read-through for IDXX and has contributed to sector-wide sentiment compression. Implication: Sets a low bar for IDXX — any outperformance vs. the sector narrative could be a positive catalyst.
• July 28, 2026 — BofA Animal Health Sector Note: Neutral on IDXX; VetSource Q2 data -1.9% YoY. Bank of America maintained a Neutral rating on IDXX ahead of Q2 earnings, noting VetSource data showed Q2 vet visit declines of -1.9% YoY (consistent with Q1 trends) and July data showing -4% YoY (likely holiday-distorted). BofA expects visits to decline ~2% for FY 2026 with no sustained improvement. Implication: Confirms the visit headwind is real but not accelerating vs. Q1; IDXX's -1.5% assumption is slightly more optimistic than BofA's -2% view.
• Q2 2026 (during quarter) — CATalyst Council Report: Vet visit declines forecast through 2030, FY2027 trough of -2.2%. CATalyst Council (board includes former IDXX CEO Jon Ayers) published market analysis forecasting vet visit declines continuing past 2030 with a FY2027 trough of -2.2%. BofA noted this "contributed to pressure on Idexx shares during the quarter." Implication: A key sentiment overhang that IDXX management will need to address on the Q2 call — particularly given the former CEO's board involvement.
• May 27, 2026 — Stifel Jaws & Paws Conference: CEO Erickson reaffirms full-year confidence; FNA ramp on track. New CEO Mike Erickson made his first major public appearance at the Stifel conference, reaffirming the full-year forecast and providing constructive color on FNA rollout progress, Cancer DX traction, and AI strategy. Implication: Confirms no guidance revision risk from management's perspective; new CEO's tone is confident and execution-focused.
• May 15, 2026 — Shareholder Governance Reforms Approved: Board declassification and special meeting rights. IDEXX shareholders approved major governance reforms at the annual meeting, including board declassification and special meeting rights (8-K filed May 15, 2026). Implication: Positive for long-term shareholder alignment; not a near-term earnings catalyst.
• May 14, 2026 — 2026 Investor Day Announced: Scheduled for August 2026. IDEXX announced its 2026 Investor Day, with CEO Erickson indicating he plans to share more on AI advancements at the event. The Q1 2026 earnings call referenced an August Investor Day. Implication: A potential near-term catalyst post-Q2 earnings — management has signaled the Investor Day will provide more detail on MultiQ Dx, AI strategy, and long-term growth targets.
• May 12, 2026 — CEO Transition Completed: Mike Erickson succeeds Jay Mazelsky as CEO. Mike Erickson officially became President and CEO following the annual meeting on May 12, 2026. Jay Mazelsky transitioned to Executive Chair with a planned retirement in May 2027. Erickson has signaled strategic continuity with added emphasis on AI and software. Implication: Leadership transition risk is largely resolved; Erickson's Stifel appearance demonstrated confident command of the business.
• June 2, 2026 — Elanco William Blair Conference: March/April rebound in U.S. pet health; corporate clinic channel growing 12% in Q1. Elanco's commentary at the William Blair conference provided a more constructive read on the U.S. pet health market than Zoetis, noting a rebound after a weather-impacted Q1 start and strong corporate clinic growth. Implication: Partial positive offset to the Zoetis negative read-through; suggests the market may not be uniformly weak.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives or directors since Q1 2026 earnings. All Form 4 activity since May 5, 2026 consists of routine equity compensation events (RSU vesting/settlement, annual director equity grants, and one tax-withholding share surrender) — none of which carry informational signal about management's view of the upcoming print.

Directors receiving annual grants (May 12, 2026): Britt Irene Chang, Bruce L. Claflin, Stuart Essig, Joseph L. Hooley, Daniel M. Junius, Lawrence D. Kingsley, Karen Peacock, Sam Samad, Sophie V. Vandebroek.

Directors with RSU vesting (May 7, 2026): Joseph L. Hooley (158 shares), Daniel M. Junius (257 shares), Lawrence D. Kingsley (339 shares), Karen Peacock (101 shares), M. Anne Szostak (257 shares), Sophie V. Vandebroek (257 shares).

Conclusion: The complete absence of open-market purchases or discretionary sales by any executive or director since Q1 2026 earnings is neither bullish nor bearish — it simply reflects that all Form 4 activity is routine compensation-related. There is no insider signal to read into the Q2 2026 print. Source: SEC Form 4 Filings Database (Insider Transaction Data).

— End of IDXX Q2 2026 Earnings Preview —